Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Jan-Feb;107(1):44-7.

Antiplatelet therapy for stroke prevention in atrial fibrillation

Nadish Garg  1 , Arun Kumar, Greg C Flaker
Affiliations
Review

Antiplatelet therapy for stroke prevention in atrial fibrillation

Nadish Garg et al. Mo Med. 2010 Jan-Feb.

Abstract

Warfarin has been the cornerstone therapy for stroke prevention in non-valvular atrial fibrillation (NVAF), particularly in patients at high risk of ischemic stroke or thromboembolism. Warfarin use in NVAF results in a 64% relative reduction in the incidence of ischemic stroke and several trials have demonstrated warfarin to be superior to aspirin alone (relative risk reduction-22%). However, anticoagulation with warfarin is associated with increased bleeding, especially in the elderly population. Anticoagaulation with warfarin requires close monitoring of the international standardized ratio (INR), which can be inconvenient to patients. Additionally, large numbers of patients on coumadin have a subtherapeutic INR level, which increases the risk of thromboembolic episodes. In part due to the above mentioned reasons, anticoagulation with warfarin is underutilized for stroke prevention.

PubMed Disclaimer

Figures

Figures 1A & 1B
Figures 1A & 1B
Relative effects of antithrombotic therapies on all stroke from randomized trials in patients with atrial fibrillation. 1A. Antiplatelet agents compared with placebo or no treatment in 8 randomized trials. 1B. Adjusted-dose warfarin compared with antiplatelet agents in 11 randomized trials.
Figure 2
Figure 2
Risk Benefit per 1,000 Patients with Warfarin in Comparison to Aspirin, Aspirin plus Clopidrogel and Placebo
Figure 3
Figure 3
Risk and Benefit of Dual Aspirin and Clopidogrel Therapy in the ACTIVE-A Trial
None
See this image and copyright information in PMC

References

    1. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation. Ann Intern Med. 2007 Jun 19;146(12):857–67. - PubMed
    1. Waldo AL, Becker RC, Tapson VF, Colgan KJ for the NABOR Steering Committee. Hospitalized Patients With Atrial Fibrillation and a High Risk of Stroke Are Not Being Provided With Adequate Anticoagulation. J Am Coll Cardiol. 2005 Nov 1;46(9):1729–36. - PubMed
    1. Bungard TJ, Ghali WA, Teo KK, McAlister FA, Tsuyuki RT. Why Do Patients With Atrial Fibrillation Not Receive Warfarin? Arch Intern Med. 2000 Jan 10;160(1):41–6. - PubMed
    1. Hylek EM, D’Antonio J, Evans-Molina C, Shea C, Henault LE, Regan S. Translating the Results of Randomized Trials into Clinical Practice: The Challenge of Warfarin Candidacy Among Hospitalized Elderly Patients With Atrial Fibrillation. Stroke. 2006 Apr 1;37(4):1075–80. - PubMed
    1. Grau AJ, Ruf A, Vogt A, Lichy C, Buggle F, Patscheke H, Hacke W. Increased fraction of circulating activated platelets in acute and previous cerebrovascular ischemia. Thromb Haemost. 1998;80(2):298–301. - PubMed

MeSH terms

LinkOut - more resources